Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05396456 · ClinicalTrials.gov registry record · NA

Autologous Muscle Fiber Fragment Injections

A NA study of Fecal Incontinence, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT05396456 is a NA study of Fecal Incontinence that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 10 participants, below the 335-participant average among 22 other Fecal Incontinence trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05396456, a NA study of Fecal Incontinence, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

To regenerate functional anal sphincter muscle using muscle fiber fragments that contain muscle precursor cells (MPCs)

Conditions Studied

Interventions

  • PROCEDURE Muscle Fiber Fragment (MFF) Injections

Study Locations (1)

North Carolina

  • Wake Forest University Health Sciences - Winston-Salem

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2023-01-12
Est. Completion 2029-12
Phase NA

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT05396456

The ClinicalTrials.gov registry entry for NCT05396456 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 335-participant average among 22 other Fecal Incontinence trials with a reported enrollment target (97% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Fecal Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Muscle Fiber Fragment (MFF) Injections is the first listed.

NCT05396456 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05396456 about?

NCT05396456 is a clinical study titled "Autologous Muscle Fiber Fragment Injections". To regenerate functional anal sphincter muscle using muscle fiber fragments that contain muscle precursor cells (MPCs)

What is the current status of trial NCT05396456?

This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2023-01-12. Estimated completion is 2029-12.

What conditions does trial NCT05396456 study?

This clinical trial studies the following conditions: Fecal Incontinence.

What interventions are being tested in trial NCT05396456?

The interventions under investigation include: Muscle Fiber Fragment (MFF) Injections (PROCEDURE).

Who is sponsoring clinical trial NCT05396456?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05396456 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fecal Incontinence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.